These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11176026)

  • 1. Regulatory affairs as they affect invasive cardiology.
    Fischell RE
    J Invasive Cardiol; 2001 Feb; 13(2):139-40; discussion 158-70. PubMed ID: 11176026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The regulation of home diagnostic tests for genetic disorders: can the FDA deny a premarket application on the basis of the device's social impacts?
    Kerouac JD
    J Biolaw Bus; 2002; 5(1):34-43. PubMed ID: 12751500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroenterology and urology devices; effective date of requirement for premarket approval of the implanted mechanical/hydraulic urinary continence device. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Sep; 65(187):57726-32. PubMed ID: 11503643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathways to approval of pediatric cardiac devices in the United States: challenges and solutions.
    Beekman RH; Duncan BW; Hagler DJ; Jones TK; Kugler JD; Moore JW; Jenkins KJ;
    Pediatrics; 2009 Jul; 124(1):e155-62. PubMed ID: 19564262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic planning for U.S. premarket approval submissions.
    Donawa M
    Med Device Technol; 2006 Sep; 17(7):21-3. PubMed ID: 17039953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA notifications. FC2 female condom receives FDA approval.
    AIDS Alert; 2009 May; 24(5):58-9. PubMed ID: 19455720
    [No Abstract]   [Full Text] [Related]  

  • 8. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new FDA combination products programme.
    Donawa M
    Med Device Technol; 2002 Oct; 13(8):25-8. PubMed ID: 12416330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical devices; reclassification of six cardiovascular preamendments class III devices into class II. Final rule.
    Food and Drug Administration
    Fed Regist; 2001 Apr; 66(69):18540-2. PubMed ID: 11721689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will new FDA rules hasten device approval?
    Hosp Mater Manage; 2003 Jul; 28(7):2, 16. PubMed ID: 12889277
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
    Burkhart CG
    J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
    [No Abstract]   [Full Text] [Related]  

  • 14. Obstetric and gynecology devices; effective date of requirement for premarket approval for glans sheath devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(115):40848-9. PubMed ID: 12068899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA delays, unaccountability, raise health care costs and imperil American consumers' lives.
    Lammi GG
    Healthspan; 1995 Mar; 12(3):8-12. PubMed ID: 10166126
    [No Abstract]   [Full Text] [Related]  

  • 17. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical devices: the obvious, the readily-accepted, and the surprising.
    Tolomeo DE; Clarke LA
    J Health Life Sci Law; 2008 Jul; 1(4):117, 119-44. PubMed ID: 18717154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cosmetic medical devices and their FDA regulation.
    Newburger AE
    Arch Dermatol; 2006 Feb; 142(2):225-8. PubMed ID: 16490851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.